相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Haizhen Wang et al.
NATURE (2017)
LC-MS-MS quantitative analysis reveals the association between FTO and DNA methylation
Yuting Zhu et al.
PLOS ONE (2017)
A pathology atlas of the human cancer transcriptome
Mathias Uhlen et al.
SCIENCE (2017)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang et al.
CANCER CELL (2017)
Endogenous DNA Damage as a Source of Genomic Instability in Cancer
Anthony Tubbs et al.
CELL (2017)
Targeting CDK4 and CDK6: From Discovery to Therapy
Charles J. Sherr et al.
CANCER DISCOVERY (2016)
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer
Nidal E. Muvarak et al.
CANCER CELL (2016)
A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence
Mariana Acevedo et al.
CANCER RESEARCH (2016)
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
H. S. Rugo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
CDK4/6 Inhibitors : Promising Opportunities beyond Breast Cancer
Joline S. J. Lim et al.
CANCER DISCOVERY (2016)
IDH1/2 Mutants Inhibit TET-Promoted Oxidation of RNA 5mC to 5hmC
Qiang Xu et al.
PLOS ONE (2016)
DNA damage and the balance between survival and death in cancer biology
Wynand P. Roos et al.
NATURE REVIEWS CANCER (2016)
DNA repair, genome stability and cancer: a historical perspective
Penny A. Jeggo et al.
NATURE REVIEWS CANCER (2016)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A mechanism for the suppression of homologous recombination in G1 cells
Alexandre Orthwein et al.
NATURE (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Large-scale RNA-Seq Transcriptome Analysis of 4043 Cancers and 548 Normal Tissue Controls across 12 TCGA Cancer Types
Li Peng et al.
SCIENTIFIC REPORTS (2015)
Therapeutic opportunities within the DNA damage response
Laurence H. Pearl et al.
NATURE REVIEWS CANCER (2015)
Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression
Yoonjin Lee et al.
NATURE (2014)
Open Comet: An automated tool for comet assay image analysis
Benjamin M. Gyori et al.
REDOX BIOLOGY (2014)
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein et al.
NATURE GENETICS (2013)
Push back to respond better: regulatory inhibition of the DNA double-strand break response
Stephanie Panier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
The Requirement for Cyclin D Function in Tumor Maintenance
Yoon Jong Choi et al.
CANCER CELL (2012)
Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Catherine M. Sawai et al.
CANCER CELL (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
Jeffry L. Dean et al.
CELL CYCLE (2012)
Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
Jeffry L. Dean et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Bryan A. Gibson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
Marta Puyol et al.
CANCER CELL (2010)
Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein
Qingkai Yang et al.
CANCER CELL (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
J. L. Dean et al.
ONCOGENE (2010)
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Konstantin J. Dedes et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Retinoblastoma deficiency increases chemosensitivity in lung cancer
William A. Zagorski et al.
CANCER RESEARCH (2007)
The comet assay: a method to measure DNA damage in individual cells
Peggy L. Olive et al.
NATURE PROTOCOLS (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
An in vitro procedure for evaluation of early stage oxidative stress in an established fish cell line applied to investigation of PHAH and pesticide toxicity
M Ruiz-Leal et al.
MARINE ENVIRONMENTAL RESEARCH (2004)
Pathways of DNA double-strand break repair during the mammalian cell cycle
K Rothkamm et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
分享论文
